Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.71 -0.37 (-0.84%)
Streaming Delayed Price Updated: 9:49 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 141,056
Open 44.00
Bid (Size) 43.50 (1,200)
Ask (Size) 43.74 (800)
Prev. Close 44.08
Today's Range 43.20 - 44.04
52wk Range 32.38 - 49.62
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
Via MarketBeat
News headline image
Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
Exelixis (EXEL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+0.3%
+0.3%
1 Month
-0.2%
-0.2%
3 Month
+2.5%
+2.5%
6 Month
+16.5%
+16.5%
1 Year
+27.8%
+27.8%

More News

Read More
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
Via Chartmill
News headline image
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
Via Chartmill
News headline image
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
2 Stocks That Could Soar This Year ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
From Exelixis, Inc.
Via Business Wire
News headline image
2 Healthcare Stocks to Buy for 2026 and Beyond ↗
Via The Motley Fool
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
Via Chartmill
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
From Equity Insider
Via GlobeNewswire
News headline image
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
From Exelixis, Inc.
Via Business Wire
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
News headline image
S&P 500 Surges as Congress Nears End to Protracted Government Shutdown
Via MarketMinute
Topics Economy Regulatory Compliance Stocks

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 43.71
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 02/18/26 09:49 AM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 13.77B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.